ID   TFR1_HUMAN              Reviewed;         760 AA.
AC   P02786; D3DXB0; Q1HE24; Q59G55; Q9UCN0; Q9UCU5; Q9UDF9; Q9UK21;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2006, sequence version 2.
DT   18-JUN-2025, entry version 269.
DE   RecName: Full=Transferrin receptor protein 1;
DE            Short=TR;
DE            Short=TfR;
DE            Short=TfR1;
DE            Short=Trfr;
DE   AltName: Full=T9;
DE   AltName: Full=p90;
DE   AltName: CD_antigen=CD71;
DE   Contains:
DE     RecName: Full=Transferrin receptor protein 1, serum form;
DE              Short=sTfR;
GN   Name=TFRC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-142.
RX   PubMed=6090955; DOI=10.1038/311675b0;
RA   Schneider C., Owen M.J., Banville D., Williams J.G.;
RT   "Primary structure of human transferrin receptor deduced from the mRNA
RT   sequence.";
RL   Nature 311:675-678(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-142.
RX   PubMed=6094009; DOI=10.1016/0092-8674(84)90004-7;
RA   McClelland A., Kuhn L.C., Ruddle F.H.;
RT   "The human transferrin receptor gene: genomic organization, and the
RT   complete primary structure of the receptor deduced from a cDNA sequence.";
RL   Cell 39:267-274(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=9358047; DOI=10.1016/s0378-1119(97)00356-9;
RA   Evans P., Kemp J.;
RT   "Exon/intron structure of the human transferrin receptor gene.";
RL   Gene 199:123-131(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RA   Wheeler D.L.;
RT   "Molecular and evolutionary studies of the transferrin receptor.";
RL   Thesis (1999), University of Iowa, United States.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 101-119 (STFR).
RX   PubMed=2229063; DOI=10.1016/s0021-9258(17)30627-0;
RA   Shih Y.J., Baynes R.D., Hudson B.G., Flowers C.H., Skikne B.S., Cook J.D.;
RT   "Serum transferrin receptor is a truncated form of tissue receptor.";
RL   J. Biol. Chem. 265:19077-19081(1990).
RN   [10]
RP   PROTEIN SEQUENCE OF 101-123 (STFR), AND CHARACTERIZATION.
RC   TISSUE=Erythroleukemia;
RX   PubMed=1871153; DOI=10.3181/00379727-197-43276;
RA   Baynes R.D., Shih Y.J., Hudson B.G., Cook J.D.;
RT   "Characterization of transferrin receptor released by K562 erythroleukemia
RT   cells.";
RL   Proc. Soc. Exp. Biol. Med. 197:416-423(1991).
RN   [11]
RP   PROTEIN SEQUENCE OF 288-302; 694-708 AND 721-730.
RC   TISSUE=Prostatic carcinoma;
RX   PubMed=7864799; DOI=10.1042/bj3060129;
RA   Coppolino M., Migliorini M., Argraves W.S., Dedhar S.;
RT   "Identification of a novel form of the alpha 3 integrin subunit: covalent
RT   association with transferrin receptor.";
RL   Biochem. J. 306:129-134(1995).
RN   [12]
RP   PROTEIN SEQUENCE OF 680-696.
RX   PubMed=1380674; DOI=10.1038/358764a0;
RA   Chicz R.M., Urban R.G., Lane W.S., Gorga J.C., Stern L.J., Vignali D.A.A.,
RA   Strominger J.L.;
RT   "Predominant naturally processed peptides bound to HLA-DR1 are derived from
RT   MHC-related molecules and are heterogeneous in size.";
RL   Nature 358:764-768(1992).
RN   [13]
RP   FUNCTION.
RX   PubMed=3568132; DOI=10.1016/0092-8674(87)90295-9;
RA   Rothenberger S., Iacopetta B.J., Kuhn L.C.;
RT   "Endocytosis of the transferrin receptor requires the cytoplasmic domain
RT   but not its phosphorylation site.";
RL   Cell 49:423-431(1987).
RN   [14]
RP   PALMITOYLATION AT CYS-62 AND CYS-67, AND INTERCHAIN DISULFIDE BOND AT
RP   CYS-89 AND CYS-98.
RX   PubMed=3582362; DOI=10.1002/j.1460-2075.1987.tb04758.x;
RA   Jing S., Trowbridge I.S.;
RT   "Identification of the intermolecular disulfide bonds of the human
RT   transferrin receptor and its lipid-attachment site.";
RL   EMBO J. 6:327-331(1987).
RN   [15]
RP   MUTAGENESIS OF CYSTEINE RESIDUES INVOLVED IN INTERMOLECULAR BONDS.
RX   PubMed=2507316; DOI=10.1002/j.1460-2075.1989.tb08347.x;
RA   Alvarez E., Girones N., Davis R.J.;
RT   "Intermolecular disulfide bonds are not required for the expression of the
RT   dimeric state and functional activity of the transferrin receptor.";
RL   EMBO J. 8:2231-2240(1989).
RN   [16]
RP   MUTAGENESIS OF TYR-20.
RX   PubMed=2327986; DOI=10.1042/bj2670031;
RA   Alvarez E., Girones N., Davis R.J.;
RT   "A point mutation in the cytoplasmic domain of the transferrin receptor
RT   inhibits endocytosis.";
RL   Biochem. J. 267:31-35(1990).
RN   [17]
RP   INTERNALIZATION SEQUENCE, AND MUTAGENESIS OF TYR-20.
RX   PubMed=2298808; DOI=10.1083/jcb.110.2.283;
RA   Jing S., Spencer T., Miller K., Hopkins C., Trowbridge I.S.;
RT   "Role of the human transferrin receptor cytoplasmic domain in endocytosis:
RT   localization of a specific signal sequence for internalization.";
RL   J. Cell Biol. 110:283-294(1990).
RN   [18]
RP   GLYCOSYLATION AT THR-104.
RX   PubMed=1421756; DOI=10.1093/glycob/2.4.345;
RA   Do S.-I., Cummings R.D.;
RT   "Presence of O-linked oligosaccharide on a threonine residue in the human
RT   transferrin receptor.";
RL   Glycobiology 2:345-353(1992).
RN   [19]
RP   GLYCOSYLATION AT THR-104.
RX   PubMed=1421757; DOI=10.1093/glycob/2.4.355;
RA   Hayes G.R., Enns C.A., Lucas J.J.;
RT   "Identification of the O-linked glycosylation site of the human transferrin
RT   receptor.";
RL   Glycobiology 2:355-359(1992).
RN   [20]
RP   MUTAGENESIS OF 20-TYR--PHE-23; TYR-20; THR-21 AND PHE-23.
RX   PubMed=8408022; DOI=10.1016/s0021-9258(20)80596-1;
RA   Collawn J.F., Lai A., Domingo D.L., Fitch M., Hatton S., Trowbridge I.S.;
RT   "YTRF is the conserved internalization signal of the transferrin receptor,
RT   and a second YTRF signal at position 31-34 enhances endocytosis.";
RL   J. Biol. Chem. 268:21686-21692(1993).
RN   [21]
RP   GLYCOSYLATION AT ASN-727, AND STRUCTURE OF CARBOHYDRATES ON ASN-727.
RX   PubMed=7780197; DOI=10.1093/glycob/5.2.227;
RA   Hayes G.R., Williams A., Costello C.E., Enns C.A., Lucas J.J.;
RT   "The critical glycosylation site of human transferrin receptor contains a
RT   high-mannose oligosaccharide.";
RL   Glycobiology 5:227-232(1995).
RN   [22]
RP   IDENTIFICATION OF LIGAND-BINDING DOMAIN.
RX   PubMed=8631371; DOI=10.1111/j.1432-1033.1996.0009u.x;
RA   Buchegger F., Trowbridge I.S., Liu L.F., White S., Collawn J.F.;
RT   "Functional analysis of human/chicken transferrin receptor chimeras
RT   indicates that the carboxy-terminal region is important for ligand
RT   binding.";
RL   Eur. J. Biochem. 235:9-17(1996).
RN   [23]
RP   MUTAGENESIS OF ARG-646; GLY-647 AND ASP-648.
RX   PubMed=10377239; DOI=10.1042/bj3410011;
RA   Dubljevic V., Sali A., Goding J.W.;
RT   "A conserved RGD (Arg-Gly-Asp) motif in the transferrin receptor is
RT   required for binding to transferrin.";
RL   Biochem. J. 341:11-14(1999).
RN   [24]
RP   MUTAGENESIS.
RX   PubMed=11800564; DOI=10.1006/jmbi.2001.5048;
RA   West A.P. Jr., Giannetti A.M., Herr A.B., Bennett M.J., Nangiana J.S.,
RA   Pierce J.R., Weiner L.P., Snow P.M., Bjorkman P.J.;
RT   "Mutational analysis of the transferrin receptor reveals overlapping HFE
RT   and transferrin binding sites.";
RL   J. Mol. Biol. 313:385-397(2001).
RN   [25]
RP   INTERACTION WITH SH3BP4.
RX   PubMed=16325581; DOI=10.1016/j.cell.2005.10.021;
RA   Tosoni D., Puri C., Confalonieri S., Salcini A.E., De Camilli P.,
RA   Tacchetti C., Di Fiore P.P.;
RT   "TTP specifically regulates the internalization of the transferrin
RT   receptor.";
RL   Cell 123:875-888(2005).
RN   [26]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-251.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [28]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H., Mangini N.J.,
RA   Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R., Yamagishi S.,
RA   Shabanowitz J., Hearing V.J., Wu C., Appella E., Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [29]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH MACHUPO VIRUS PROTEIN
RP   GLYCOPROTEIN COMPLEX.
RX   PubMed=17287727; DOI=10.1038/nature05539;
RA   Radoshitzky S.R., Abraham J., Spiropoulou C.F., Kuhn J.H., Nguyen D.,
RA   Li W., Nagel J., Schmidt P.J., Nunberg J.H., Andrews N.C., Farzan M.,
RA   Choe H.;
RT   "Transferrin receptor 1 is a cellular receptor for New World haemorrhagic
RT   fever arenaviruses.";
RL   Nature 446:92-96(2007).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-21, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [31]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH GUANARITO VIRUS
RP   GLYCOPROTEIN COMPLEX, INTERACTION WITH JUNIN VIRUS GLYCOPROTEIN COMPLEX,
RP   AND INTERACTION WITH MACHUPO VIRUS GLYCOPROTEIN COMPLEX.
RX   PubMed=18268337; DOI=10.1073/pnas.0709254105;
RA   Radoshitzky S.R., Kuhn J.H., Spiropoulou C.F., Albarino C.G., Nguyen D.P.,
RA   Salazar-Bravo J., Dorfman T., Lee A.S., Wang E., Ross S.R., Choe H.,
RA   Farzan M.;
RT   "Receptor determinants of zoonotic transmission of New World hemorrhagic
RT   fever arenaviruses.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2664-2669(2008).
RN   [32]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-251 AND ASN-727.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [33]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-251.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-linked
RT   cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-20, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [39]
RP   FUNCTION, AND STEAROYLATION.
RX   PubMed=26214738; DOI=10.1038/nature14601;
RA   Senyilmaz D., Virtue S., Xu X., Tan C.Y., Griffin J.L., Miller A.K.,
RA   Vidal-Puig A., Teleman A.A.;
RT   "Regulation of mitochondrial morphology and function by stearoylation of
RT   TFR1.";
RL   Nature 525:124-128(2015).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [41]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH RABV PROTEIN G
RP   (MICROBIAL INFECTION).
RX   PubMed=36779762; DOI=10.1128/jvi.01612-22;
RA   Wang X., Wen Z., Cao H., Luo J., Shuai L., Wang C., Ge J., Wang X., Bu Z.,
RA   Wang J.;
RT   "Transferrin Receptor Protein 1 Is an Entry Factor for Rabies Virus.";
RL   J. Virol. 97:e0161222-e0161222(2023).
RN   [42]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH SARS-COV-2 SPIKE PROTEIN S
RP   (MICROBIAL INFECTION), AND INTERACTION WITH RABIES VIRUS PROTEIN G
RP   (MICROBIAL INFECTION).
RX   PubMed=36779763; DOI=10.1128/jvi.01611-22;
RA   Wang X., Wen Z., Cao H., Luo J., Shuai L., Wang C., Ge J., Wang X., Bu Z.,
RA   Wang J.;
RT   "Transferrin Receptor Protein 1 Cooperates with mGluR2 To Mediate the
RT   Internalization of Rabies Virus and SARS-CoV-2.";
RL   J. Virol. 97:e0161122-e0161122(2023).
RN   [43]
RP   ELECTRON MICROSCOPY, AND PHOSPHORYLATION AT SER-24.
RX   PubMed=9782058; DOI=10.1016/s0969-2126(98)00124-5;
RA   Fuchs H., Luecken W., Tauber R., Engel A.;
RT   "Structural model of phospholipid-reconstituted human transferrin receptor
RT   derived by electron microscopy.";
RL   Structure 6:1235-1243(1998).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 121-760, AND GLYCOSYLATION AT
RP   ASN-251; ASN-317 AND ASN-727.
RX   PubMed=10531064; DOI=10.1126/science.286.5440.779;
RA   Lawrence C.M., Ray S., Babyonyshev M., Galluser R., Borhani D.W.,
RA   Harrison S.C.;
RT   "Crystal structure of the ectodomain of human transferrin receptor.";
RL   Science 286:779-782(1999).
RN   [45]
RP   VARIANT SER-142.
RX   PubMed=11702220; DOI=10.1007/s004390100599;
RA   Douabin-Gicquel V., Soriano N., Ferran H., Wojcik F., Palierne E.,
RA   Tamim S., Jovelin T., McKie A.T., Le Gall J.-Y., David V., Mosser J.;
RT   "Identification of 96 single nucleotide polymorphisms in eight genes
RT   involved in iron metabolism: efficiency of bioinformatic extraction
RT   compared with a systematic sequencing approach.";
RL   Hum. Genet. 109:393-401(2001).
RN   [46]
RP   INVOLVEMENT IN IMD46, VARIANT IMD46 HIS-20, CHARACTERIZATION OF VARIANT
RP   IMD46 HIS-20, FUNCTION, AND INTERACTION WITH STEAP3.
RX   PubMed=26642240; DOI=10.1038/ng.3465;
RA   Jabara H.H., Boyden S.E., Chou J., Ramesh N., Massaad M.J., Benson H.,
RA   Bainter W., Fraulino D., Rahimov F., Sieff C., Liu Z.J., Alshemmari S.H.,
RA   Al-Ramadi B.K., Al-Dhekri H., Arnaout R., Abu-Shukair M., Vatsayan A.,
RA   Silver E., Ahuja S., Davies E.G., Sola-Visner M., Ohsumi T.K.,
RA   Andrews N.C., Notarangelo L.D., Fleming M.D., Al-Herz W., Kunkel L.M.,
RA   Geha R.S.;
RT   "A missense mutation in TFRC, encoding transferrin receptor 1, causes
RT   combined immunodeficiency.";
RL   Nat. Genet. 48:74-78(2016).
CC   -!- FUNCTION: Cellular uptake of iron occurs via receptor-mediated
CC       endocytosis of ligand-occupied transferrin receptor into specialized
CC       endosomes (PubMed:26214738). Endosomal acidification leads to iron
CC       release. The apotransferrin-receptor complex is then recycled to the
CC       cell surface with a return to neutral pH and the concomitant loss of
CC       affinity of apotransferrin for its receptor. Transferrin receptor is
CC       necessary for development of erythrocytes and the nervous system (By
CC       similarity). A second ligand, the hereditary hemochromatosis protein
CC       HFE, competes for binding with transferrin for an overlapping C-
CC       terminal binding site. Positively regulates T and B cell proliferation
CC       through iron uptake (PubMed:26642240). Acts as a lipid sensor that
CC       regulates mitochondrial fusion by regulating activation of the JNK
CC       pathway (PubMed:26214738). When dietary levels of stearate (C18:0) are
CC       low, promotes activation of the JNK pathway, resulting in HUWE1-
CC       mediated ubiquitination and subsequent degradation of the mitofusin
CC       MFN2 and inhibition of mitochondrial fusion (PubMed:26214738). When
CC       dietary levels of stearate (C18:0) are high, TFRC stearoylation
CC       inhibits activation of the JNK pathway and thus degradation of the
CC       mitofusin MFN2 (PubMed:26214738). Mediates uptake of NICOL1 into
CC       fibroblasts where it may regulate extracellular matrix production (By
CC       similarity). {ECO:0000250|UniProtKB:Q62351,
CC       ECO:0000269|PubMed:26214738, ECO:0000269|PubMed:26642240,
CC       ECO:0000269|PubMed:3568132}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for new-world
CC       arenaviruses: Guanarito, Junin and Machupo virus.
CC       {ECO:0000269|PubMed:17287727, ECO:0000269|PubMed:18268337}.
CC   -!- FUNCTION: (Microbial infection) Acts as a host entry factor for rabies
CC       virus that hijacks the endocytosis of TFRC to enter cells.
CC       {ECO:0000269|PubMed:36779762, ECO:0000269|PubMed:36779763}.
CC   -!- FUNCTION: (Microbial infection) Acts as a host entry factor for SARS-
CC       CoV, MERS-CoV and SARS-CoV-2 viruses that hijack the endocytosis of
CC       TFRC to enter cells. {ECO:0000269|PubMed:36779762}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Binds one transferrin or HFE
CC       molecule per subunit. Binds the HLA class II histocompatibility
CC       antigen, DR1. Interacts with SH3BP3. Interacts with STEAP3; facilitates
CC       TFRC endocytosis in erythroid precursor cells (PubMed:26642240).
CC       Interacts with GRM2 (PubMed:36779763). {ECO:0000269|PubMed:16325581,
CC       ECO:0000269|PubMed:26642240, ECO:0000269|PubMed:36779763}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Guanarito, Junin and
CC       Machupo arenavirus glycoprotein complex (PubMed:17287727,
CC       PubMed:18268337). {ECO:0000269|PubMed:17287727,
CC       ECO:0000269|PubMed:18268337}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with rabies virus protein G.
CC       {ECO:0000269|PubMed:36779762, ECO:0000269|PubMed:36779763}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS-CoV-2 spike protein
CC       S. {ECO:0000269|PubMed:36779762, ECO:0000269|PubMed:36779763}.
CC   -!- INTERACTION:
CC       P02786; P02768: ALB; NbExp=2; IntAct=EBI-355727, EBI-714423;
CC       P02786; Q13520: AQP6; NbExp=3; IntAct=EBI-355727, EBI-13059134;
CC       P02786; Q3SXY8: ARL13B; NbExp=3; IntAct=EBI-355727, EBI-11343438;
CC       P02786; P07307-3: ASGR2; NbExp=3; IntAct=EBI-355727, EBI-12808270;
CC       P02786; Q96HA4-2: C1orf159; NbExp=3; IntAct=EBI-355727, EBI-17586094;
CC       P02786; Q96BA8: CREB3L1; NbExp=3; IntAct=EBI-355727, EBI-6942903;
CC       P02786; Q5JX71: FAM209A; NbExp=3; IntAct=EBI-355727, EBI-18304435;
CC       P02786; Q96KR6: FAM210B; NbExp=3; IntAct=EBI-355727, EBI-18938272;
CC       P02786; P02794: FTH1; NbExp=2; IntAct=EBI-355727, EBI-713259;
CC       P02786; O00258: GET1; NbExp=3; IntAct=EBI-355727, EBI-18908258;
CC       P02786; Q8TDT2: GPR152; NbExp=3; IntAct=EBI-355727, EBI-13345167;
CC       P02786; Q30201: HFE; NbExp=3; IntAct=EBI-355727, EBI-1028850;
CC       P02786; Q30201-1: HFE; NbExp=3; IntAct=EBI-355727, EBI-15489346;
CC       P02786; P31937: HIBADH; NbExp=3; IntAct=EBI-355727, EBI-11427100;
CC       P02786; Q8TAF8: LHFPL5; NbExp=3; IntAct=EBI-355727, EBI-2820517;
CC       P02786; Q9GZY8-5: MFF; NbExp=3; IntAct=EBI-355727, EBI-11956541;
CC       P02786; O14880: MGST3; NbExp=3; IntAct=EBI-355727, EBI-724754;
CC       P02786; O75459: PAGE1; NbExp=3; IntAct=EBI-355727, EBI-2559100;
CC       P02786; Q86WH2: RASSF3; NbExp=3; IntAct=EBI-355727, EBI-2845202;
CC       P02786; Q8NC24: RELL2; NbExp=3; IntAct=EBI-355727, EBI-10269209;
CC       P02786; Q96TC7: RMDN3; NbExp=3; IntAct=EBI-355727, EBI-1056589;
CC       P02786; O43765: SGTA; NbExp=6; IntAct=EBI-355727, EBI-347996;
CC       P02786; Q9P0V3: SH3BP4; NbExp=6; IntAct=EBI-355727, EBI-1049513;
CC       P02786; Q14973: SLC10A1; NbExp=3; IntAct=EBI-355727, EBI-3923031;
CC       P02786; P54219-3: SLC18A1; NbExp=3; IntAct=EBI-355727, EBI-17595455;
CC       P02786; P02787: TF; NbExp=7; IntAct=EBI-355727, EBI-714319;
CC       P02786; PRO_0000035715 [P02787]: TF; NbExp=4; IntAct=EBI-355727, EBI-40201768;
CC       P02786; P02786: TFRC; NbExp=4; IntAct=EBI-355727, EBI-355727;
CC       P02786; A5K736: PVX_094255; Xeno; NbExp=12; IntAct=EBI-355727, EBI-20622076;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17081065};
CC       Single-pass type II membrane protein {ECO:0000269|PubMed:17081065}.
CC       Melanosome {ECO:0000269|PubMed:17081065}. Note=Identified by mass
CC       spectrometry in melanosome fractions from stage I to stage IV.
CC       {ECO:0000269|PubMed:17081065}.
CC   -!- SUBCELLULAR LOCATION: [Transferrin receptor protein 1, serum form]:
CC       Secreted {ECO:0000269|PubMed:17081065}.
CC   -!- INDUCTION: Regulated by cellular iron levels through binding of the
CC       iron regulatory proteins, IRP1 and IRP2, to iron-responsive elements in
CC       the 3'-UTR. Up-regulated upon mitogenic stimulation.
CC   -!- PTM: Stearoylated by ZDHHC6 which inhibits TFRC-mediated activation of
CC       the JNK pathway and promotes mitochondrial fragmentation
CC       (PubMed:26214738). Stearoylation does not affect iron uptake
CC       (PubMed:26214738). {ECO:0000269|PubMed:26214738}.
CC   -!- PTM: N- and O-glycosylated, phosphorylated and palmitoylated. The serum
CC       form is only glycosylated. {ECO:0000269|PubMed:1421756,
CC       ECO:0000269|PubMed:1421757, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973,
CC       ECO:0000269|PubMed:3582362}.
CC   -!- PTM: Proteolytically cleaved on Arg-100 to produce the soluble serum
CC       form (sTfR).
CC   -!- PTM: Palmitoylated on both Cys-62 and Cys-67. Cys-62 seems to be the
CC       major site of palmitoylation. {ECO:0000269|PubMed:3582362}.
CC   -!- DISEASE: Immunodeficiency 46 (IMD46) [MIM:616740]: An autosomal
CC       recessive primary immunodeficiency disorder characterized by early-
CC       onset chronic diarrhea, recurrent infections, hypo- or
CC       agammaglobulinemia, normal lymphocyte counts, intermittent neutropenia,
CC       and intermittent thrombocytopenia. {ECO:0000269|PubMed:26642240}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: Serum transferrin receptor (sTfR) is used as a means of
CC       detecting erythropoietin (EPO) misuse by athletes and as a diagnostic
CC       test for anemia resulting from a number of conditions including
CC       rheumatoid arthritis, pregnancy, irritable bowel syndrome and in HIV
CC       patients.
CC   -!- MISCELLANEOUS: Canine and feline parvoviruses bind human and feline
CC       transferrin receptors and use these receptors to enter and infect
CC       cells.
CC   -!- SIMILARITY: Belongs to the peptidase M28 family. M28B subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92491.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/259/TFRC";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X01060; CAA25527.1; -; mRNA.
DR   EMBL; M11507; AAA61153.1; -; mRNA.
DR   EMBL; AF187320; AAF04564.1; -; Genomic_DNA.
DR   EMBL; AB209254; BAD92491.1; ALT_INIT; mRNA.
DR   EMBL; DQ496099; ABF47088.1; -; Genomic_DNA.
DR   EMBL; CH471191; EAW53670.1; -; Genomic_DNA.
DR   EMBL; CH471191; EAW53673.1; -; Genomic_DNA.
DR   EMBL; BC001188; AAH01188.1; -; mRNA.
DR   CCDS; CCDS3312.1; -.
DR   PIR; A93343; JXHU.
DR   RefSeq; NP_001121620.1; NM_001128148.3.
DR   RefSeq; NP_001300894.1; NM_001313965.1.
DR   RefSeq; NP_001300895.1; NM_001313966.1.
DR   RefSeq; NP_003225.2; NM_003234.4.
DR   PDB; 1CX8; X-ray; 3.20 A; A/B/C/D/E/F/G/H=122-760.
DR   PDB; 1DE4; X-ray; 2.80 A; C/F/I=121-760.
DR   PDB; 1SUV; EM; 7.50 A; A/B=122-760.
DR   PDB; 2NSU; EM; 27.00 A; A/B=122-760.
DR   PDB; 3KAS; X-ray; 2.40 A; A=121-760.
DR   PDB; 3S9L; X-ray; 3.22 A; A/B=120-760.
DR   PDB; 3S9M; X-ray; 3.32 A; A/B=120-760.
DR   PDB; 3S9N; X-ray; 3.25 A; A/B=120-760.
DR   PDB; 6D03; EM; 3.68 A; A/B=121-760.
DR   PDB; 6D04; EM; 3.74 A; A/B=121-760.
DR   PDB; 6D05; EM; 3.80 A; A/B=121-760.
DR   PDB; 6GSR; EM; 5.50 A; Ab/Aq=121-760.
DR   PDB; 6H5I; EM; 3.90 A; Ab/Aq=121-760.
DR   PDB; 6OKD; X-ray; 1.85 A; A/B=121-760.
DR   PDB; 6W3H; X-ray; 3.38 A; C/D=296-326.
DR   PDB; 6WRV; X-ray; 2.47 A; A/B/E=121-759.
DR   PDB; 6WRW; X-ray; 2.84 A; A/B=121-760.
DR   PDB; 6WRX; X-ray; 3.07 A; A/B=121-760.
DR   PDB; 6Y76; X-ray; 1.98 A; A/B=197-378.
DR   PDB; 7ZQS; EM; 2.54 A; B/D=1-760.
DR   PDB; 8P0Z; X-ray; 1.88 A; A=197-299, A=332-377.
DR   PDBsum; 1CX8; -.
DR   PDBsum; 1DE4; -.
DR   PDBsum; 1SUV; -.
DR   PDBsum; 2NSU; -.
DR   PDBsum; 3KAS; -.
DR   PDBsum; 3S9L; -.
DR   PDBsum; 3S9M; -.
DR   PDBsum; 3S9N; -.
DR   PDBsum; 6D03; -.
DR   PDBsum; 6D04; -.
DR   PDBsum; 6D05; -.
DR   PDBsum; 6GSR; -.
DR   PDBsum; 6H5I; -.
DR   PDBsum; 6OKD; -.
DR   PDBsum; 6W3H; -.
DR   PDBsum; 6WRV; -.
DR   PDBsum; 6WRW; -.
DR   PDBsum; 6WRX; -.
DR   PDBsum; 6Y76; -.
DR   PDBsum; 7ZQS; -.
DR   PDBsum; 8P0Z; -.
DR   AlphaFoldDB; P02786; -.
DR   EMDB; EMD-0046; -.
DR   EMDB; EMD-0140; -.
DR   EMDB; EMD-1288; -.
DR   EMDB; EMD-14874; -.
DR   EMDB; EMD-7783; -.
DR   EMDB; EMD-7784; -.
DR   EMDB; EMD-7785; -.
DR   SMR; P02786; -.
DR   BioGRID; 112895; 521.
DR   CORUM; P02786; -.
DR   DIP; DIP-2736N; -.
DR   ELM; P02786; -.
DR   FunCoup; P02786; 1848.
DR   IntAct; P02786; 177.
DR   MINT; P02786; -.
DR   STRING; 9606.ENSP00000376197; -.
DR   ChEMBL; CHEMBL3712860; -.
DR   DrugBank; DB13949; Ferric cation.
DR   DrugBank; DB15617; Ferric derisomaltose.
DR   DrugBank; DB14490; Ferrous ascorbate.
DR   DrugBank; DB14491; Ferrous fumarate.
DR   DrugBank; DB14488; Ferrous gluconate.
DR   DrugBank; DB14501; Ferrous glycine sulfate.
DR   DrugBank; DB14489; Ferrous succinate.
DR   DrugBank; DB13257; Ferrous sulfate anhydrous.
DR   DrugBank; DB01592; Iron.
DR   DrugBank; DB14520; Tetraferric tricitrate decahydrate.
DR   DrugCentral; P02786; -.
DR   MEROPS; M28.972; -.
DR   TCDB; 2.B.93.1.1; the trasferrin-mediated heptapeptide-decorated nanodrug (thn) family.
DR   TCDB; 9.B.229.1.1; the transferrin receptor, cd71, (tfr) family.
DR   GlyConnect; 607; 36 N-Linked glycans (5 sites), 5 O-Linked glycans (1 site).
DR   GlyCosmos; P02786; 7 sites, 57 glycans.
DR   GlyGen; P02786; 18 sites, 92 N-linked glycans (7 sites), 11 O-linked glycans (6 sites).
DR   iPTMnet; P02786; -.
DR   MetOSite; P02786; -.
DR   PhosphoSitePlus; P02786; -.
DR   SwissPalm; P02786; -.
DR   BioMuta; TFRC; -.
DR   DMDM; 108935939; -.
DR   CPTAC; non-CPTAC-2704; -.
DR   jPOST; P02786; -.
DR   MassIVE; P02786; -.
DR   PaxDb; 9606-ENSP00000353224; -.
DR   PeptideAtlas; P02786; -.
DR   ProteomicsDB; 51595; -.
DR   Pumba; P02786; -.
DR   ABCD; P02786; 239 sequenced antibodies.
DR   Antibodypedia; 4559; 3139 antibodies from 49 providers.
DR   DNASU; 7037; -.
DR   Ensembl; ENST00000360110.9; ENSP00000353224.4; ENSG00000072274.14.
DR   Ensembl; ENST00000392396.7; ENSP00000376197.3; ENSG00000072274.14.
DR   Ensembl; ENST00000698280.1; ENSP00000513646.1; ENSG00000072274.14.
DR   Ensembl; ENST00000698291.1; ENSP00000513654.1; ENSG00000072274.14.
DR   GeneID; 7037; -.
DR   KEGG; hsa:7037; -.
DR   MANE-Select; ENST00000360110.9; ENSP00000353224.4; NM_001128148.3; NP_001121620.1.
DR   UCSC; uc003fvz.5; human.
DR   AGR; HGNC:11763; -.
DR   CTD; 7037; -.
DR   DisGeNET; 7037; -.
DR   GeneCards; TFRC; -.
DR   HGNC; HGNC:11763; TFRC.
DR   HPA; ENSG00000072274; Low tissue specificity.
DR   MalaCards; TFRC; -.
DR   MIM; 190010; gene.
DR   MIM; 616740; phenotype.
DR   OpenTargets; ENSG00000072274; -.
DR   Orphanet; 476113; Combined immunodeficiency due to TFRC deficiency.
DR   VEuPathDB; HostDB:ENSG00000072274; -.
DR   eggNOG; KOG2195; Eukaryota.
DR   GeneTree; ENSGT01030000234598; -.
DR   InParanoid; P02786; -.
DR   OMA; YQDSNWI; -.
DR   OrthoDB; 5841748at2759; -.
DR   PAN-GO; P02786; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; P02786; -.
DR   PathwayCommons; P02786; -.
DR   Reactome; R-HSA-432722; Golgi Associated Vesicle Biogenesis.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8980692; RHOA GTPase cycle.
DR   Reactome; R-HSA-9013026; RHOB GTPase cycle.
DR   Reactome; R-HSA-9013106; RHOC GTPase cycle.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013406; RHOQ GTPase cycle.
DR   Reactome; R-HSA-9013407; RHOH GTPase cycle.
DR   Reactome; R-HSA-9013408; RHOG GTPase cycle.
DR   Reactome; R-HSA-9013409; RHOJ GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   Reactome; R-HSA-917977; Transferrin endocytosis and recycling.
DR   Reactome; R-HSA-9696270; RND2 GTPase cycle.
DR   Reactome; R-HSA-9696273; RND1 GTPase cycle.
DR   Reactome; R-HSA-9725554; Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin.
DR   SignaLink; P02786; -.
DR   SIGNOR; P02786; -.
DR   BioGRID-ORCS; 7037; 570 hits in 1175 CRISPR screens.
DR   ChiTaRS; TFRC; human.
DR   EvolutionaryTrace; P02786; -.
DR   GeneWiki; TFRC; -.
DR   GenomeRNAi; 7037; -.
DR   Pharos; P02786; Tclin.
DR   PRO; PR:P02786; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P02786; protein.
DR   Bgee; ENSG00000072274; Expressed in endothelial cell and 211 other cell types or tissues.
DR   ExpressionAtlas; P02786; baseline and differential.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005905; C:clathrin-coated pit; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:MGI.
DR   GO; GO:0005769; C:early endosome; IEA:Ensembl.
DR   GO; GO:0005768; C:endosome; IDA:MGI.
DR   GO; GO:0010008; C:endosome membrane; IDA:CAFA.
DR   GO; GO:0009897; C:external side of plasma membrane; IGI:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:1990712; C:HFE-transferrin receptor complex; IDA:BHF-UCL.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:CAFA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0098944; C:postsynaptic recycling endosome membrane; IEA:Ensembl.
DR   GO; GO:0055037; C:recycling endosome; IDA:UniProtKB.
DR   GO; GO:0055038; C:recycling endosome membrane; IEA:Ensembl.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI.
DR   GO; GO:0030544; F:Hsp70 protein binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:ARUK-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0004998; F:transferrin receptor activity; IDA:UniProtKB.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0006953; P:acute-phase response; IEA:Ensembl.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IDA:MGI.
DR   GO; GO:0006879; P:intracellular iron ion homeostasis; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IMP:UniProtKB.
DR   GO; GO:0006826; P:iron ion transport; IDA:UniProtKB.
DR   GO; GO:0060586; P:multicellular organismal-level iron ion homeostasis; IDA:UniProt.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:ARUK-UCL.
DR   GO; GO:0010637; P:negative regulation of mitochondrial fusion; IMP:UniProtKB.
DR   GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IDA:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:ARUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:0045830; P:positive regulation of isotype switching; IDA:UniProtKB.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IMP:ARUK-UCL.
DR   GO; GO:0031334; P:positive regulation of protein-containing complex assembly; IMP:ARUK-UCL.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IDA:UniProtKB.
DR   GO; GO:0031623; P:receptor internalization; IDA:UniProtKB.
DR   GO; GO:0099072; P:regulation of postsynaptic membrane neurotransmitter receptor levels; IEA:Ensembl.
DR   GO; GO:0046688; P:response to copper ion; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0010039; P:response to iron ion; IEA:Ensembl.
DR   GO; GO:0010042; P:response to manganese ion; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0033572; P:transferrin transport; IDA:UniProtKB.
DR   GO; GO:0150104; P:transport across blood-brain barrier; NAS:ARUK-UCL.
DR   CDD; cd09848; M28_TfR; 1.
DR   CDD; cd02128; PA_TfR; 1.
DR   FunFam; 1.20.930.40:FF:000002; Transferrin receptor protein 1; 1.
DR   FunFam; 3.40.630.10:FF:000045; Transferrin receptor protein 1; 1.
DR   FunFam; 3.50.30.30:FF:000010; Transferrin receptor protein 1; 1.
DR   Gene3D; 3.50.30.30; -; 1.
DR   Gene3D; 1.20.930.40; Transferrin receptor-like, dimerisation domain; 1.
DR   Gene3D; 3.40.630.10; Zn peptidases; 1.
DR   InterPro; IPR046450; PA_dom_sf.
DR   InterPro; IPR003137; PA_domain.
DR   InterPro; IPR007484; Peptidase_M28.
DR   InterPro; IPR039373; Peptidase_M28B.
DR   InterPro; IPR007365; TFR-like_dimer_dom.
DR   InterPro; IPR036757; TFR-like_dimer_dom_sf.
DR   InterPro; IPR037324; TfR1/2_PA.
DR   PANTHER; PTHR10404; N-ACETYLATED-ALPHA-LINKED ACIDIC DIPEPTIDASE; 1.
DR   PANTHER; PTHR10404:SF26; TRANSFERRIN RECEPTOR PROTEIN 1; 1.
DR   Pfam; PF02225; PA; 1.
DR   Pfam; PF04389; Peptidase_M28; 1.
DR   Pfam; PF04253; TFR_dimer; 1.
DR   SUPFAM; SSF52025; PA domain; 1.
DR   SUPFAM; SSF47672; Transferrin receptor-like dimerisation domain; 1.
DR   SUPFAM; SSF53187; Zn-dependent exopeptidases; 1.
DR   neXtProt; NX_P02786; -.
DR   PharmGKB; PA36478; -.
DR   TreeFam; TF312981; -.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Direct protein sequencing; Disease variant;
KW   Disulfide bond; Endocytosis; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction; Lipoprotein;
KW   Membrane; Palmitate; Phosphoprotein; Proteomics identification; Receptor;
KW   Reference proteome; Secreted; Signal-anchor; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..760
FT                   /note="Transferrin receptor protein 1"
FT                   /id="PRO_0000174132"
FT   CHAIN           101..760
FT                   /note="Transferrin receptor protein 1, serum form"
FT                   /id="PRO_0000292265"
FT   TOPO_DOM        1..67
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        68..88
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        89..760
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          223..313
FT                   /note="PA"
FT   REGION          1..67
FT                   /note="Mediates interaction with SH3BP4"
FT                   /evidence="ECO:0000269|PubMed:16325581"
FT   REGION          569..760
FT                   /note="Ligand-binding"
FT   MOTIF           20..23
FT                   /note="Endocytosis signal"
FT                   /evidence="ECO:0000269|PubMed:2298808"
FT   MOTIF           58..61
FT                   /note="Stop-transfer sequence"
FT                   /evidence="ECO:0000303|PubMed:6090955"
FT   MOTIF           646..648
FT                   /note="Cell attachment site; required for binding to
FT                   transferrin"
FT   SITE            100..101
FT                   /note="Cleavage; by trypsin; to produce soluble form"
FT   MOD_RES         10
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         19
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62351"
FT   MOD_RES         20
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         21
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         24
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:9782058"
FT   LIPID           62
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:3582362"
FT   LIPID           67
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000305|PubMed:3582362"
FT   CARBOHYD        104
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:1421756,
FT                   ECO:0000269|PubMed:1421757"
FT                   /id="CAR_000072"
FT   CARBOHYD        251
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:10531064,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:19349973, ECO:0007744|PDB:1CX8"
FT   CARBOHYD        317
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:10531064,
FT                   ECO:0007744|PDB:1CX8"
FT   CARBOHYD        727
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:10531064,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:7780197,
FT                   ECO:0007744|PDB:1CX8"
FT                   /id="CAR_000173"
FT   DISULFID        89
FT                   /note="Interchain"
FT                   /evidence="ECO:0000269|PubMed:3582362"
FT   DISULFID        98
FT                   /note="Interchain"
FT                   /evidence="ECO:0000269|PubMed:3582362"
FT   VARIANT         20
FT                   /note="Y -> H (in IMD46; increases protein expression;
FT                   increases cell surface expression on T and B cells;
FT                   increases soluble form level; impairs receptor
FT                   internalization; impairs transferrin transport; impairs T
FT                   and B cell proliferation as well as B cell class-switching;
FT                   interacts with STEAP3; doesn't affect receptor
FT                   internalization in erythroid precursor cells;
FT                   dbSNP:rs863225436)"
FT                   /evidence="ECO:0000269|PubMed:26642240"
FT                   /id="VAR_076365"
FT   VARIANT         142
FT                   /note="G -> S (in dbSNP:rs3817672)"
FT                   /evidence="ECO:0000269|PubMed:11702220,
FT                   ECO:0000269|PubMed:6090955, ECO:0000269|PubMed:6094009"
FT                   /id="VAR_012737"
FT   VARIANT         212
FT                   /note="L -> V (in dbSNP:rs41301381)"
FT                   /id="VAR_051806"
FT   VARIANT         420
FT                   /note="G -> S (in dbSNP:rs41295879)"
FT                   /id="VAR_051807"
FT   VARIANT         677
FT                   /note="R -> H (in dbSNP:rs41298067)"
FT                   /id="VAR_051808"
FT   MUTAGEN         9..12
FT                   /note="FSNL->YTRF: Only 80% as active as wild-type
FT                   receptor."
FT   MUTAGEN         20..34
FT                   /note="YTRFSLARQVDGDNS->PPGYSLARQVDYTRF: No influence on
FT                   endocytic uptake of the receptor."
FT   MUTAGEN         20..23
FT                   /note="YTRF->PPGY: Only 16% as active as wild-type
FT                   receptor."
FT                   /evidence="ECO:0000269|PubMed:8408022"
FT   MUTAGEN         20
FT                   /note="Y->C: Only 35% as active as wild-type receptor."
FT                   /evidence="ECO:0000269|PubMed:2298808,
FT                   ECO:0000269|PubMed:2327986, ECO:0000269|PubMed:8408022"
FT   MUTAGEN         20
FT                   /note="Y->G: Only 20% as active as wild-type receptor."
FT                   /evidence="ECO:0000269|PubMed:2298808,
FT                   ECO:0000269|PubMed:2327986, ECO:0000269|PubMed:8408022"
FT   MUTAGEN         21
FT                   /note="T->F: Only 88% as active as wild-type receptor."
FT                   /evidence="ECO:0000269|PubMed:8408022"
FT   MUTAGEN         21
FT                   /note="T->TA: Only 14% as active as wild-type receptor."
FT                   /evidence="ECO:0000269|PubMed:8408022"
FT   MUTAGEN         21
FT                   /note="T->TAA: Only 19% as active as wild-type receptor."
FT                   /evidence="ECO:0000269|PubMed:8408022"
FT   MUTAGEN         23
FT                   /note="F->Y: Only 48% as active as wild-type receptor."
FT                   /evidence="ECO:0000269|PubMed:8408022"
FT   MUTAGEN         31..34
FT                   /note="GDNS->YTRF: 2-fold increase of the endocytic uptake
FT                   of the receptor."
FT   MUTAGEN         47..50
FT                   /note="NADN->YTRF: 1.27-fold increase of the endocytic
FT                   uptake of the receptor."
FT   MUTAGEN         619
FT                   /note="L->A: 20-fold reduced affinity for transferrin
FT                   receptor. No binding to HFE."
FT   MUTAGEN         622
FT                   /note="V->A: No significant effect on binding to
FT                   transferrin nor HFE."
FT   MUTAGEN         623
FT                   /note="R->A: No significant effect on binding to
FT                   transferrin nor HFE."
FT   MUTAGEN         629
FT                   /note="R->A: >5-fold reduced affinity for transferrin.
FT                   >10-fold reduced affinity for HFE."
FT   MUTAGEN         640
FT                   /note="Q->A: No effect on binding to transferrin. >10-fold
FT                   reduced affinity for HFE."
FT   MUTAGEN         641
FT                   /note="W->A: No significant effect on binding to
FT                   transferrin nor HFE."
FT   MUTAGEN         643
FT                   /note="Y->A: 20-fold reduced affinity for transferrin. No
FT                   binding to HFE."
FT   MUTAGEN         644
FT                   /note="S->A: No significant effect on binding to
FT                   transferrin nor HFE."
FT   MUTAGEN         646
FT                   /note="R->A,H: No binding to transferrin."
FT                   /evidence="ECO:0000269|PubMed:10377239"
FT   MUTAGEN         646
FT                   /note="R->K: 5% binding to transferrin."
FT                   /evidence="ECO:0000269|PubMed:10377239"
FT   MUTAGEN         647
FT                   /note="G->A: Large effect on affinity for transferrin.
FT                   4-fold reduced affinity for HFE."
FT                   /evidence="ECO:0000269|PubMed:10377239"
FT   MUTAGEN         648
FT                   /note="D->A: 16% binding to transferrin."
FT                   /evidence="ECO:0000269|PubMed:10377239"
FT   MUTAGEN         648
FT                   /note="D->E: 57% binding to transferrin."
FT                   /evidence="ECO:0000269|PubMed:10377239"
FT   MUTAGEN         650
FT                   /note="F->Q: >5-fold reduced affinity for transferrin.
FT                   >10-fold reduced affinity for HFE."
FT   CONFLICT        104
FT                   /note="T -> K (in Ref. 10; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        109
FT                   /note="R -> V (in Ref. 10; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        123
FT                   /note="Y -> T (in Ref. 10; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   HELIX           124..136
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           141..146
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           150..152
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           160..175
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          179..192
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           195..197
FT                   /evidence="ECO:0007829|PDB:6W3H"
FT   STRAND          199..204
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   TURN            205..208
FT                   /evidence="ECO:0007829|PDB:3KAS"
FT   STRAND          209..214
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          220..222
FT                   /evidence="ECO:0007829|PDB:3S9L"
FT   STRAND          226..230
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          232..234
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          236..238
FT                   /evidence="ECO:0007829|PDB:6WRV"
FT   HELIX           240..245
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          253..259
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          260..262
FT                   /evidence="ECO:0007829|PDB:6WRV"
FT   HELIX           264..273
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          278..282
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   TURN            285..287
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          303..306
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          308..310
FT                   /evidence="ECO:0007829|PDB:3S9L"
FT   STRAND          311..313
FT                   /evidence="ECO:0007829|PDB:1CX8"
FT   HELIX           317..319
FT                   /evidence="ECO:0007829|PDB:6WRV"
FT   STRAND          334..336
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           339..346
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          349..352
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           355..357
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          364..367
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          372..377
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          380..393
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          396..408
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          411..413
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   TURN            416..419
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           420..440
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          445..454
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           456..458
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           461..468
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   TURN            469..473
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           474..476
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          478..483
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          491..498
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           500..502
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           503..510
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          512..514
FT                   /evidence="ECO:0007829|PDB:6WRW"
FT   TURN            516..518
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          520..522
FT                   /evidence="ECO:0007829|PDB:3KAS"
FT   HELIX           528..531
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           541..546
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          552..558
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   TURN            564..567
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           573..579
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           583..602
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          603..606
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           613..626
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           629..634
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           640..662
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           668..678
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   TURN            679..682
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           683..685
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          688..690
FT                   /evidence="ECO:0007829|PDB:3S9L"
FT   TURN            692..694
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   TURN            700..702
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          705..708
FT                   /evidence="ECO:0007829|PDB:3S9M"
FT   HELIX           709..718
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          719..723
FT                   /evidence="ECO:0007829|PDB:6WRX"
FT   HELIX           728..748
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   STRAND          750..752
FT                   /evidence="ECO:0007829|PDB:6OKD"
FT   HELIX           753..755
FT                   /evidence="ECO:0007829|PDB:6WRV"
SQ   SEQUENCE   760 AA;  84871 MW;  C886F14000D90154 CRC64;
     MMDQARSAFS NLFGGEPLSY TRFSLARQVD GDNSHVEMKL AVDEEENADN NTKANVTKPK
     RCSGSICYGT IAVIVFFLIG FMIGYLGYCK GVEPKTECER LAGTESPVRE EPGEDFPAAR
     RLYWDDLKRK LSEKLDSTDF TGTIKLLNEN SYVPREAGSQ KDENLALYVE NQFREFKLSK
     VWRDQHFVKI QVKDSAQNSV IIVDKNGRLV YLVENPGGYV AYSKAATVTG KLVHANFGTK
     KDFEDLYTPV NGSIVIVRAG KITFAEKVAN AESLNAIGVL IYMDQTKFPI VNAELSFFGH
     AHLGTGDPYT PGFPSFNHTQ FPPSRSSGLP NIPVQTISRA AAEKLFGNME GDCPSDWKTD
     STCRMVTSES KNVKLTVSNV LKEIKILNIF GVIKGFVEPD HYVVVGAQRD AWGPGAAKSG
     VGTALLLKLA QMFSDMVLKD GFQPSRSIIF ASWSAGDFGS VGATEWLEGY LSSLHLKAFT
     YINLDKAVLG TSNFKVSASP LLYTLIEKTM QNVKHPVTGQ FLYQDSNWAS KVEKLTLDNA
     AFPFLAYSGI PAVSFCFCED TDYPYLGTTM DTYKELIERI PELNKVARAA AEVAGQFVIK
     LTHDVELNLD YERYNSQLLS FVRDLNQYRA DIKEMGLSLQ WLYSARGDFF RATSRLTTDF
     GNAEKTDRFV MKKLNDRVMR VEYHFLSPYV SPKESPFRHV FWGSGSHTLP ALLENLKLRK
     QNNGAFNETL FRNQLALATW TIQGAANALS GDVWDIDNEF
//
